Articles with public access mandates - Matti AnnalaLearn more
Not available anywhere: 15
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
BC Parker, M Engels, M Annala, W Zhang
The Journal of pathology 232 (1), 4-15, 2014
Mandates: US National Institutes of Health
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ...
Nature 608 (7921), 199-208, 2022
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Prostate …
Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer
C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ...
European urology 78 (6), 834-844, 2020
Mandates: Canadian Institutes of Health Research, Prostate Cancer Canada
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ...
Clinical Cancer Research 27 (6), 1650-1662, 2021
Mandates: Canadian Institutes of Health Research, Prostate Cancer Canada
Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer
E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ...
Clinical Cancer Research 26 (5), 1114-1125, 2020
Mandates: Canadian Institutes of Health Research, Prostate Cancer Canada
MiR‐1247‐5p is overexpressed in castration resistant prostate cancer and targets MYCBP2
M Scaravilli, KP Porkka, A Brofeldt, M Annala, TLJ Tammela, GW Jenster, ...
The Prostate 75 (8), 798-805, 2015
Mandates: Academy of Finland
Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition
M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ...
Clinical Cancer Research 27 (16), 4610-4623, 2021
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Prostate …
Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ...
The Journal of pathology 246 (2), 244-253, 2018
Mandates: Prostate Cancer Canada
Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma
JVW Bacon, M Annala, M Soleimani, JM Lavoie, A So, ME Gleave, L Fazli, ...
Clinical Genitourinary Cancer 18 (4), 322-331. e2, 2020
Mandates: Canadian Institutes of Health Research
A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian cancer trials group study IND205
SJ Hotte, KN Chi, AM Joshua, D Tu, RJ Macfarlane, RW Gregg, ...
Clinical Genitourinary Cancer 17 (3), 201-208. e1, 2019
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research
Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection
ES Park, JP Yan, RA Ang, JH Lee, X Deng, SP Duffy, K Beja, M Annala, ...
Lab on a Chip 18 (12), 1736-1749, 2018
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Overexpression of SNORD114-3 marks acute promyelocytic leukemia
T Liuksiala, KJ Teittinen, K Granberg, M Heinäniemi, M Annala, M Mäki, ...
Leukemia 28 (1), 233-236, 2014
Mandates: National Institute of Health and Medical Research, France
Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
SH Tolmeijer, E Boerrigter, T Sumiyoshi, EM Kwan, SWS Ng, M Annala, ...
Clinical Cancer Research 29 (15), 2835-2844, 2023
Mandates: Netherlands Organisation for Health Research and Development
Moving toward personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer
ECP Chedgy, M Annala, K Beja, EW Warner, ME Gleave, KN Chi, ...
Clinical genitourinary cancer 14 (2), e233-e236, 2016
Mandates: Canadian Cancer Society
Genomic features of lung-recurrent hormone-sensitive prostate cancer
NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ...
JCO precision oncology 6, e2100543, 2022
Mandates: Canadian Institutes of Health Research
Available somewhere: 45
The somatic genomic landscape of glioblastoma
CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ...
cell 155 (2), 462-477, 2013
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Integrated genomic characterization of endometrial carcinoma
DA Levine, ...
Nature 497 (7447), 67-73, 2013
Mandates: US National Institutes of Health
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
Mandates: US National Institutes of Health
The evolutionary history of lethal metastatic prostate cancer
G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ...
Nature 520 (7547), 353-357, 2015
Mandates: US National Institutes of Health, Research Foundation (Flanders), Academy of …
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
Mandates: Canadian Cancer Society, Prostate Cancer Canada
Publication and funding information is determined automatically by a computer program